Gossamer Bio’s (GOSS) “Neutral” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reissued their neutral rating on shares of Gossamer Bio (NASDAQ:GOSS) in a research report sent to investors on Monday, Marketbeat.com reports.

Other equities research analysts have also issued reports about the stock. HC Wainwright reduced their target price on shares of Gossamer Bio from $10.00 to $5.00 and set a “buy” rating on the stock in a report on Friday, March 6th. Royal Bank Of Canada upgraded shares of Gossamer Bio to an “outperform” rating in a research note on Tuesday, February 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Gossamer Bio in a research note on Thursday, January 22nd. Oppenheimer decreased their target price on Gossamer Bio from $12.00 to $3.00 and set an “outperform” rating for the company in a report on Thursday, March 5th. Finally, Wall Street Zen cut Gossamer Bio from a “hold” rating to a “sell” rating in a research note on Friday, January 23rd. Four investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Gossamer Bio currently has an average rating of “Hold” and an average target price of $5.43.

Gossamer Bio Price Performance

Shares of NASDAQ:GOSS opened at $0.38 on Monday. The firm has a market capitalization of $89.54 million, a PE ratio of -0.51 and a beta of 2.08. Gossamer Bio has a 1 year low of $0.32 and a 1 year high of $3.87. The firm’s 50-day moving average is $1.52 and its two-hundred day moving average is $2.40.

Gossamer Bio (NASDAQ:GOSS) last posted its quarterly earnings data on Tuesday, March 17th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The business had revenue of $13.80 million during the quarter, compared to analysts’ expectations of $7.53 million. Gossamer Bio had a negative net margin of 351.49% and a negative return on equity of 1,774.72%. Analysts expect that Gossamer Bio will post -0.28 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Rockefeller Capital Management L.P. raised its holdings in shares of Gossamer Bio by 496.7% in the 4th quarter. Rockefeller Capital Management L.P. now owns 60,866 shares of the company’s stock valued at $189,000 after purchasing an additional 50,666 shares in the last quarter. Corient Private Wealth LLC lifted its position in shares of Gossamer Bio by 19,123.7% during the 4th quarter. Corient Private Wealth LLC now owns 3,845,885 shares of the company’s stock worth $11,922,000 after purchasing an additional 3,825,879 shares during the last quarter. Invesco Ltd. grew its stake in shares of Gossamer Bio by 36.0% during the fourth quarter. Invesco Ltd. now owns 478,909 shares of the company’s stock worth $1,485,000 after purchasing an additional 126,823 shares in the last quarter. Mercer Global Advisors Inc. ADV grew its stake in shares of Gossamer Bio by 52.3% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 23,983 shares of the company’s stock worth $74,000 after purchasing an additional 8,239 shares in the last quarter. Finally, Beacon Pointe Advisors LLC purchased a new position in Gossamer Bio in the fourth quarter valued at $34,000. Institutional investors and hedge funds own 81.23% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.